Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by D. Boral Capital

Can-Fite BioPharma (NYSE:CANF) was upgraded by stock analysts at D. Boral Capital from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $7.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 94.44% from the stock’s previous close.

Separately, HC Wainwright set a $5.00 price objective on shares of Can-Fite BioPharma and gave the company a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Can-Fite BioPharma Trading Up 6.2%

CANF stock traded up $0.21 during trading on Wednesday, hitting $3.60. The company had a trading volume of 58,036 shares, compared to its average volume of 809,390. The business has a 50 day moving average of $3.41 and a 200 day moving average of $4.83. The firm has a market capitalization of $2.36 million, a price-to-earnings ratio of -2.00 and a beta of 1.09. Can-Fite BioPharma has a fifty-two week low of $2.83 and a fifty-two week high of $23.40.

Institutional Trading of Can-Fite BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in CANF. Rhumbline Advisers boosted its holdings in Can-Fite BioPharma by 42.4% during the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after buying an additional 11,388 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Can-Fite BioPharma during the 4th quarter worth $41,000. Finally, Sabby Management LLC grew its holdings in shares of Can-Fite BioPharma by 80.3% in the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after acquiring an additional 626,306 shares during the last quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).